Drug Pricing ‘Biggest Offenders’ Are Annual Increases On Widely Used Brands
Executive Summary
Express Scripts Chief Medical Officer Steve Miller suggests that caps on annual price increases could significantly ease payer concerns over drug pricing.
You may also be interested in...
Why Is Drug Pricing Higher In US? Study Takes Aim At R&D Argument
Amgen, Biogen, Pfizer and Teva generated more than twice their global R&D budgets with higher pricing in the US compared to Western Europe and Canada, researchers at Memorial Sloan Kettering found.
Why Is Drug Pricing Higher In US? Study Takes Aim At R&D Argument
Amgen, Biogen, Pfizer and Teva generated more than twice their global R&D budgets with higher pricing in the US compared to Western Europe and Canada, researchers at Memorial Sloan Kettering found.
Drug Pricing ‘Opacity,’ Degrees Of Transparency Debated By National Academies Panel
Second meeting of National Academies drug pricing committee was far-reaching discussion of several major themes, including PBM transparency, the political future for co-pay coupons and the next possible inflection point: the potential $1 million price tag for gene therapies.